Immuneering (IMRX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Immuneering (NASDAQ: IMRX):

• 7/12/2026 – Immuneering was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/8/2026 – Immuneering is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $17.00 price target on the stock.
• 7/8/2026 – Immuneering is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $17.00 price target on the stock.
• 7/8/2026 – Immuneering is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $17.00 price target on the stock.
• 6/24/2026 – Immuneering had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/13/2026 – Immuneering was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/1/2026 – Immuneering had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 5/19/2026 – Immuneering had its “buy” rating reaffirmed by Chardan Capital. They now have a $20.00 price target on the stock.

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.